Matches in SemOpenAlex for { <https://semopenalex.org/work/W2569203403> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W2569203403 endingPage "S955" @default.
- W2569203403 startingPage "S955" @default.
- W2569203403 abstract "The mutation profile in the Brazilian population with advanced lung adenocarcinoma remains largely unexplored and also their relationship to many other genes. Next Generation Sequencing(NGS) allows higher sensitivity and multiplexing for several genes for translational research. 80 lung adenocarcinoma patients were collected. DNA concentration and quality was determined by Qubit2.0fluorometer and Agilent2100Bioanalyzer. Genomic libraries were constructed using the TruSeq®Custom Amplicon v1.5) comprising 764 amplicons of 38genes on the Illumina-MiSeq®sequencing plataform. The 7362 genetic mutation were observed with 78% of single-nuclotide variants (SNVs) and 22% insertions and deletions. The majority of the SNVs were located in inter-genic regions or introns. EGFR were mutated in 21 (6%) of patients with 19 (57%) of mean expression. The most frequent EGFR-mutation was exon 19deletions, followed by L858R amino acid substitution in exon 21. KRAS was mutated in 26 (4%) of patients. ALK rearrangement was detected in 6 patients (4.8%). The stop gained mutation was present in PIK3CA,TP53, AXL, EGFR, RAB25, CDH1, CD276 and TGFB1. The AXL receptor tyrosine kinase gene showed 11 missense-mutations, of which 7 are considered possibly damaging (Polyphen)/deleterious(SIFT)(74/79) and 14 intronSNVs(49/80). CD44 showed 50 variants, however most of them have an undetermined significance. The clustering analysis demonstrated that a select group of AXL-related gene alterations was highlighted (Fig 1). The results suggest that genomic variants in lung adenocarcinoma tissues are complex and show that NGS is an effective way to detect novel mutations in lung cancer. 58% of patients wild type by standard testing for EGFR/KRAS/ALK have genomic changes identifiable by CGP that suggest benefit from target therapy. The AXL and CD44 genes remain a relatively unexplored target, thus we intend to increase the available data for the true translational potential of target AXL and CD44 therapy in lung cancer. CGP used when standard molecular testing for adenocarcinoma is negative can reveal additional avenues of benefit from targeted therapy." @default.
- W2569203403 created "2017-01-13" @default.
- W2569203403 creator A5003271083 @default.
- W2569203403 creator A5007732374 @default.
- W2569203403 creator A5008744408 @default.
- W2569203403 creator A5030983089 @default.
- W2569203403 creator A5033065747 @default.
- W2569203403 creator A5033604322 @default.
- W2569203403 creator A5041225203 @default.
- W2569203403 creator A5043477787 @default.
- W2569203403 creator A5050278072 @default.
- W2569203403 creator A5050659951 @default.
- W2569203403 creator A5056236088 @default.
- W2569203403 creator A5084274046 @default.
- W2569203403 creator A5087186890 @default.
- W2569203403 creator A5091844291 @default.
- W2569203403 date "2017-01-01" @default.
- W2569203403 modified "2023-10-01" @default.
- W2569203403 title "P2.03b-034 Clinical Relevant Oncogenic Drivers in Advanced Adenocarcinoma Discloses New Therapeutic Targets in Negative EGFR/ALK/KRAS Patients" @default.
- W2569203403 doi "https://doi.org/10.1016/j.jtho.2016.11.1315" @default.
- W2569203403 hasPublicationYear "2017" @default.
- W2569203403 type Work @default.
- W2569203403 sameAs 2569203403 @default.
- W2569203403 citedByCount "0" @default.
- W2569203403 crossrefType "journal-article" @default.
- W2569203403 hasAuthorship W2569203403A5003271083 @default.
- W2569203403 hasAuthorship W2569203403A5007732374 @default.
- W2569203403 hasAuthorship W2569203403A5008744408 @default.
- W2569203403 hasAuthorship W2569203403A5030983089 @default.
- W2569203403 hasAuthorship W2569203403A5033065747 @default.
- W2569203403 hasAuthorship W2569203403A5033604322 @default.
- W2569203403 hasAuthorship W2569203403A5041225203 @default.
- W2569203403 hasAuthorship W2569203403A5043477787 @default.
- W2569203403 hasAuthorship W2569203403A5050278072 @default.
- W2569203403 hasAuthorship W2569203403A5050659951 @default.
- W2569203403 hasAuthorship W2569203403A5056236088 @default.
- W2569203403 hasAuthorship W2569203403A5084274046 @default.
- W2569203403 hasAuthorship W2569203403A5087186890 @default.
- W2569203403 hasAuthorship W2569203403A5091844291 @default.
- W2569203403 hasBestOaLocation W25692034031 @default.
- W2569203403 hasConcept C104317684 @default.
- W2569203403 hasConcept C121608353 @default.
- W2569203403 hasConcept C143998085 @default.
- W2569203403 hasConcept C2775999482 @default.
- W2569203403 hasConcept C2776256026 @default.
- W2569203403 hasConcept C2781182431 @default.
- W2569203403 hasConcept C2781187634 @default.
- W2569203403 hasConcept C2908647359 @default.
- W2569203403 hasConcept C36823959 @default.
- W2569203403 hasConcept C49105822 @default.
- W2569203403 hasConcept C501734568 @default.
- W2569203403 hasConcept C502942594 @default.
- W2569203403 hasConcept C54355233 @default.
- W2569203403 hasConcept C71924100 @default.
- W2569203403 hasConcept C8185291 @default.
- W2569203403 hasConcept C86803240 @default.
- W2569203403 hasConcept C99454951 @default.
- W2569203403 hasConceptScore W2569203403C104317684 @default.
- W2569203403 hasConceptScore W2569203403C121608353 @default.
- W2569203403 hasConceptScore W2569203403C143998085 @default.
- W2569203403 hasConceptScore W2569203403C2775999482 @default.
- W2569203403 hasConceptScore W2569203403C2776256026 @default.
- W2569203403 hasConceptScore W2569203403C2781182431 @default.
- W2569203403 hasConceptScore W2569203403C2781187634 @default.
- W2569203403 hasConceptScore W2569203403C2908647359 @default.
- W2569203403 hasConceptScore W2569203403C36823959 @default.
- W2569203403 hasConceptScore W2569203403C49105822 @default.
- W2569203403 hasConceptScore W2569203403C501734568 @default.
- W2569203403 hasConceptScore W2569203403C502942594 @default.
- W2569203403 hasConceptScore W2569203403C54355233 @default.
- W2569203403 hasConceptScore W2569203403C71924100 @default.
- W2569203403 hasConceptScore W2569203403C8185291 @default.
- W2569203403 hasConceptScore W2569203403C86803240 @default.
- W2569203403 hasConceptScore W2569203403C99454951 @default.
- W2569203403 hasIssue "1" @default.
- W2569203403 hasLocation W25692034031 @default.
- W2569203403 hasOpenAccess W2569203403 @default.
- W2569203403 hasPrimaryLocation W25692034031 @default.
- W2569203403 hasRelatedWork W1983690566 @default.
- W2569203403 hasRelatedWork W2005841680 @default.
- W2569203403 hasRelatedWork W2007661090 @default.
- W2569203403 hasRelatedWork W2024276281 @default.
- W2569203403 hasRelatedWork W2068588654 @default.
- W2569203403 hasRelatedWork W2384774992 @default.
- W2569203403 hasRelatedWork W2656042639 @default.
- W2569203403 hasRelatedWork W3006198547 @default.
- W2569203403 hasRelatedWork W4281969221 @default.
- W2569203403 hasRelatedWork W4306643401 @default.
- W2569203403 hasVolume "12" @default.
- W2569203403 isParatext "false" @default.
- W2569203403 isRetracted "false" @default.
- W2569203403 magId "2569203403" @default.
- W2569203403 workType "article" @default.